维生素E剂量研究(VEDS):代谢功能障碍相关脂肪性肝病伴转氨酶升高患者的多中心随机安慰剂对照试验
这项多中心随机安慰剂对照试验纳入200例疑似MASH、CAP>280 dB/m且ALT≥60 U/L的成人,随机接受维生素E 200、400或800 IU/日或安慰剂治疗24周。结果显示三种剂量维生素E降低ALT效果相似(降幅36%-38%),均显著优于安慰剂(12%),且ALT复常率更高,未观察到安全信号。
要点
- 维生素E 200 IU/日降低ALT效果与400、800 IU/日相当,均显著优于安慰剂
- 维生素E组ALT复常率37%-50%,高于安慰剂组的22%
- 不良事件轻至中度,维生素E组与安慰剂组相似,无危及生命事件
核心结论
- 在MASLD伴转氨酶升高的患者中,维生素E 200 IU/日与其他测试剂量(400、800 IU/日)降低ALT效果相当,且未观察到安全信号。
研究设计与样本
- 多中心、随机、安慰剂对照试验,纳入200例疑似MASH、CAP>280 dB/m且ALT≥60 U/L的成人,随机接受维生素E 200、400或800 IU/日或安慰剂治疗24周。
主要发现
- 与安慰剂相比,维生素E 200、400、800 IU/日组ALT分别降低38%、36%、36%,安慰剂组降低12%(所有p≤0.001)。
- 维生素E组ALT复常率分别为49%、37%、50%,安慰剂组为22%。
- 维生素E组AST水平也显著下降;CAP和肝硬度平均降低幅度在维生素E组更大,但无统计学显著性。
- 不良事件轻至中度,无危及生命事件,维生素E组与安慰剂组相似。
关键数值与推荐
- 纳入标准:疑似MASH,振动控制瞬时弹性成像CAP>280 dB/m,血清ALT≥60 U/L。
- 干预:天然维生素E(d-α生育酚)200、400或800 IU每日一次,疗程24周。
- 主要目标:确定从基线至24周ALT降幅最大的最低有效剂量。
临床怎么用
- 对于MASLD伴转氨酶升高的患者,可考虑使用维生素E 200 IU/日作为低成本治疗选择,但需在随机对照试验背景下进一步验证。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is a leading cause of liver disease. Despite recent drug approvals, there is a need for low-cost therapies. Potential safety concerns regarding higher doses of vitamin E led to this study. APPROACH: Adults with suspected MASH, controlled attenuation parameter (CAP) score >280 dB/m on vibration-controlled transient elastography, and serum alanine aminotransferase (ALT) ≥60 U/L were randomized to 200, 400, or 800 IU of natural vitamin E (d-alpha tocopherol) or placebo once daily for 24 weeks. The primary aim was to determine the lowest effective dose of vitamin E that resulted in the greatest reduction in ALT levels from baseline to 24 weeks. Secondary aims were to assess improvements in other biomarkers of MASH, including liver fat and stiffness. RESULTS: Two hundred participants (age 47.0+13.9 y; 62% male) completed protocol-based visits. Serum ALT levels decreased similarly compared with placebo with all 3 doses of vitamin E: -38% (200 IU), -36% (400 IU), and -36% (800 IU) compared with -12% with placebo ( p ≤0.001 for all). ALT levels normalized in more patients taking vitamin E (49%, 37%, and 50%) than with placebo (22%). AST levels also decreased significantly. Mean reduction in CAP and liver stiffness was non-significantly greater in vitamin E-treated groups. Adverse events were mild to moderate, with no life-threatening events, and similar between vitamin E and placebo. CONCLUSIONS: Vitamin E administered at 200 IU/day was as effective as other doses tested in patients with MASLD and elevated aminotransferases. No safety signals were noted.
引用
- Dasarathy S, Mitchell EP, Wilson LA, et al. Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial. Hepatology. 2026. PMID: 42268981. doi:10.1097/HEP.0000000000001797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。